The paper presents insights from two scoping literature reviews examining price determinants, pricing policies, and definitions of “fair” pricing for health technologies. The findings highlight important evidence gaps regarding how pricing decisions are made, which determinants stakeholders consider most relevant, and how affordability and innovation incentives can be balanced.
Based on this evidence, the paper outlines recommendations for improving pricing approaches and strengthening the evidence base for access-oriented pricing models. It also explains how ASCERTAIN is translating research findings and stakeholder perspectives into the development of an access-based pricing model that integrates both cost- and value-based determinants.
The work was developed within ASCERTAIN Work Package 4 and led by Gesundheit Österreich GmbH, with contributions from partners across the consortium.